Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand,
CNS Drugs. 2014 Nov;28(11):1083-97. doi: 10.1007/s40263-014-0206-y.
Rasagiline (Azilect(®)) is an oral, second-generation, selective, irreversible monoamine oxidase-B (MAO-B) inhibitor approved in the US for the treatment of Parkinson's disease. In randomized, controlled trials, oral rasagiline 1 mg once daily was superior to placebo in the symptomatic treatment of early Parkinson's disease, both as monotherapy or as an adjunct to dopamine agonists. Comparisons of early-start and delayed-start treatment suggested a disease-modifying effect for rasagiline, but the results were equivocal. Rasagiline 0.5 or 1 mg/day was also superior to placebo as adjunctive therapy to levodopa in Parkinson's disease patients with motor fluctuations. Rasagiline was generally well tolerated in clinical trials, displaying a placebo-like tolerability profile in several studies. Cost-utility studies predicted that rasagiline, either as monotherapy or adjunctive therapy, would be a cost-effective treatment option. Therefore, oral rasagiline is a valuable therapeutic option for use in all stages of Parkinson's disease.
雷沙吉兰（Azilect(®)）是一种口服第二代选择性不可逆单胺氧化酶-B（MAO-B）抑制剂，已获美国批准用于治疗帕金森病。在随机对照试验中，每日口服雷沙吉兰 1mg 作为单药治疗或与多巴胺激动剂联合治疗早期帕金森病，在症状治疗方面优于安慰剂。早期开始和延迟开始治疗的比较提示雷沙吉兰具有疾病修饰作用，但结果存在争议。雷沙吉兰 0.5 或 1mg/天也优于安慰剂，作为帕金森病伴运动波动患者的左旋多巴辅助治疗。雷沙吉兰在临床试验中通常具有良好的耐受性，在几项研究中显示出与安慰剂相似的耐受性特征。成本效益研究预测，雷沙吉兰无论是单药治疗还是辅助治疗，都是一种具有成本效益的治疗选择。因此，口服雷沙吉兰是帕金森病各阶段的一种有价值的治疗选择。
